Chapter review

Fitzgerald PMHNP board review. ch15. Disorders of Children and Adolescents. This is drive 3 of 4. When I say Pause. Answer. wait, then I will give the answer. New section. Pediatric psychopharmacology: stimulants, SSRIs, black box, monitoring. Topic. FDA Black Box Warning and Antidepressant Selection. Bottom Line Summary. * **FDA-Approved Antidepressants for Pediatric Depression**: **Fluoxetine** is FDA approved for **major depressive disorder** in children aged 8 years and older, while **escitalopram** is FDA approved for adolescents aged 12 years and older. * **FDA Black Box Warning**: All antidepressant medications carry a black box warning for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults up to age 24. * **Clinical Monitoring Protocol**: Close clinical monitoring for emergent suicidality, agitation, akathisia, or behavioral changes is required, particularly during the initial 1 to 2 months of treatment or following dose titrations. * **Pediatric Dosing Dynamics**: Children and adolescents do not automatically require lower antidepressant doses than adults because youth often possess faster hepatic clearance and metabolic rates, frequently requiring adult-level dosing to achieve therapeutic efficacy. * **First-Line Treatment Approach**: Evidence-based psychotherapy, such as **cognitive behavioral therapy** (CBT), or combination therapy (CBT plus an approved SSRI), is preferred over pharmacotherapy alone for pediatric depression. * **Avoidance of Tricyclics**: **Tricyclic antidepressants** (TCAs) are not indicated or recommended as second-line treatment in pediatric depression due to lack of demonstrated efficacy and high risk of lethal cardiotoxicity in overdose. High-Yield Clinical Concepts and Board Signposts. First-Line Selection in Pediatric MDD. When selecting pharmacotherapy for a child or adolescent with **major depressive disorder**, choices are strictly limited by FDA indications. **Fluoxetine** is approved for pediatric depression down to age 8. **Escitalopram** is approved for adolescent depression down to age 12. Other SSRIs, such as **sertraline**, carry FDA approval in pediatrics for **obsessive-compulsive disorder** (age 6 and older), but not for primary pediatric depression. Safety Alert: Suicidality Black Box Warning. The FDA black box warning highlights an elevated risk of suicidal ideation and gestures in individuals under age 25 taking antidepressants. The warning does not indicate an increase in completed suicides, but reflects heightened activation and suicidal thoughts. PMHNPs must establish a clear monitoring plan at treatment initiation, educating families to report sudden mood shifts, severe restlessness, or self-harm urges immediately. Safety Alert: Cardiotoxicity of TCAs. **Tricyclic antidepressants** carry significant cardiac risks, including QTc prolongation, conduction delays, and fatal arrhythmias in overdose. Due to these safety hazards and a lack of proven efficacy in pediatric clinical trials, TCAs are avoided in children and adolescents. If an SSRI fails, the appropriate second-line step is switching to a different SSRI or an SNRI, not initiating a TCA. Board Trap: Dosing and Pharmacokinetics. A common board exam trap assumes that pediatric patients always require smaller antidepressant doses due to smaller body mass. On the exam, remember that children metabolize psychotropic medications rapidly through active liver enzyme pathways. Assuming a child needs an ineffective micro-dose will lead to treatment failure. Doses should be started low for tolerability, but titrated up to standard therapeutic levels. Fitzgerald Sample Test Question. Question 1. Katana is a 14-year-old girl seen in your clinic who meets the diagnostic criteria for **major depressive disorder**. Which of the following statements is true regarding depression treatment in children and adolescents? A) **Fluoxetine** is one of only two medications FDA approved for use with adolescents. B) Children require lower doses of antidepressants. C) Psychopharmacology is more effective than psychotherapy. D) **Tricyclic antidepressants** offer a reasonable second-line option. Pause. **Answer:** A Why It Is Correct. Option A is correct because **fluoxetine** and **escitalopram** are the only two FDA-approved antidepressants for pediatric and adolescent **major depressive disorder**. **Fluoxetine** is approved for ages 8 and older, and **escitalopram** is approved for ages 12 and older. Why the Other Choices Are Wrong. * **Option B is wrong** because children do not necessarily require lower doses of antidepressants. Due to rapid hepatic metabolism and higher clearance rates in youth, pediatric patients often require adult-equivalent doses to achieve therapeutic serum levels. * **Option C is wrong** because psychopharmacology alone is not superior to psychotherapy. Evidence demonstrates that **cognitive behavioral therapy** or combination therapy is as effective or more effective than medication alone in pediatric depression. * **Option D is wrong** because **tricyclic antidepressants** are not reasonable second-line options in youth due to lack of efficacy in pediatric depression and high lethality from cardiotoxicity in overdose. Next Study Step. Review pediatric **attention deficit hyperactivity disorder** (ADHD) stimulant vs non-stimulant prescribing rules and monitoring parameters in Fitzgerald Chapter 15. Next. Topic. Laboratory and Biological Safety Panels. FITZGERALD CH15 — Laboratory and Biological Safety Panels. Bottom Line Summary. * Height, weight, blood pressure, and pulse must be measured at baseline before initiating stimulant therapy for ADHD and monitored quarterly (every 3 months) to track growth suppression and cardiovascular safety [1, 2]. * Fluoxetine (approved for ages 8 and older) and escitalopram (approved for ages 12 and older) are the only two FDA-approved SSRIs for major depressive disorder in children and adolescents [3, 4]. * All SSRIs carry an FDA Black Box Warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 25, requiring routine monitoring for depression and suicidality [3, 5-7]. * Non-stimulants such as atomoxetine or alpha-2 adrenergic agonists (guanfacine, clonidine) represent the preferred alternative when stimulants trigger motor tics or when active substance use disorders, severe hypertension, or structural cardiac defects are present [1, 8-10]. * Second-generation antipsychotics used for irritability in autism spectrum disorder (risperidone, aripiprazole) require baseline and ongoing laboratory safety panels, including fasting plasma glucose or hemoglobin A1c, lipid panel, liver function tests, complete blood count, and prolactin levels [11-14]. * Psychotherapy or family behavioral therapy is the first-line treatment for pediatric anxiety disorders, oppositional defiant disorder, and mild depressive presentations prior to initiating psychotropic medications [2, 15-17]. Pediatric Psychopharmacology and Safety Protocols. **First-Line**: For ADHD in children aged 6 and older, stimulant medications (methylphenidate and amphetamine salts) remain the gold standard first-line treatment [2, 18, 19]. In children under age 5, behavioral therapy is the recommended first-line intervention before starting psychotropics [2, 20]. **Safety alert**: Prior to initiating stimulants, clinicians must obtain a complete personal and family cardiac history [1, 9]. Baseline measurements of height, weight, blood pressure, and pulse are required, followed by mandatory quarterly monitoring every 3 months to detect growth deceleration, hypertension, or tachycardia [1, 2]. Stimulants must be used with caution or avoided in patients with structural cardiac abnormalities, severe hypertension, motor tics, active substance use history, or severe anxiety [9, 21]. **Board trap**: A common exam trap involves assuming children require lower weight-based antidepressant doses than adults [3, 4]. Because pediatric patients exhibit rapid hepatic metabolism and higher renal clearance, they frequently require adult-equivalent therapeutic doses of SSRIs source 4. **Safety alert**: SSRIs carry a mandatory FDA Black Box Warning for heightened suicidality risk in patients under age 25 [3, 5-7]. Fluoxetine (approved for ages 8 and older) and escitalopram (approved for ages 12 and older) are the only two FDA-approved SSRIs for pediatric depression [3, 4]. Tricyclic antidepressants are never appropriate second-line options due to cardiotoxicity and fatal overdose potential [22, 23]. **First-Line**: For oppositional defiant disorder, separation anxiety disorder, and early behavioral disruptions, family behavioral therapy or psychotherapy is first-line over medication [2, 15-17]. Sample Board Questions. Question 1. Katana meets the criteria for a major depressive disorder. Which of the following is true regarding depression treatment in children? A. Fluoxetine is one of only two medications FDA approved for use with adolescents. B. Children require lower doses of antidepressants. C. Psychopharmacology is more effective than psychotherapy. D. Tricyclic antidepressants offer a reasonable second line option. Pause. Answer: A. Why correct: Fluoxetine (FDA-approved for ages 8 and older) and escitalopram (FDA-approved for ages 12 and older) are the only two FDA-approved SSRIs for major depressive disorder in children and adolescents [3, 4]. Why the other choices are wrong: * A: This statement is true and reflects national FDA guidelines [3, 4]. * B: Incorrect because children have rapid hepatic metabolism and often require adult-level therapeutic doses source 4. * C: Incorrect because psychotherapy or combination therapy is equal to or more effective than medication alone in youth source 22. * D: Incorrect because tricyclic antidepressants carry severe cardiotoxicity and fatal overdose risks, making them unsafe second-line choices [22, 23]. Question 2. When considering management of ADHD in a 15-year-old, the use of a stimulant medication should be avoided or used with caution in the presence of which of the following? Select all that apply: A. Hypertension B. Cardiac abnormality C. Type 2 diabetes D. Prior history of substance use disorder E. Presence of motor tics F. History of anxiety or agitated states Pause. Answer: A, B, D, E, F (Type 2 diabetes is the exception). Why correct: Stimulants increase sympathomimetic activity and require baseline cardiac evaluation and quarterly monitoring of blood pressure, pulse, height, and weight [1, 2, 9]. Caution or avoidance is required with hypertension, structural cardiac defects, active substance use history, motor tics, and severe anxiety or agitation [9, 21]. Why the other choices are wrong: * A: Correctly identified as a condition requiring caution due to vasopressor effects [9, 21]. * B: Correctly identified as a condition requiring caution or avoidance due to sudden cardiac death risks [9, 21]. * C: Incorrect because Type 2 diabetes does not require avoidance or special caution when starting stimulants source 21. * D: Correctly identified as a condition requiring caution due to diversion and abuse potential [9, 21]. * E: Correctly identified as a condition requiring caution because stimulants can unmask or exacerbate tics [9, 21]. * F: Correctly identified as a condition requiring caution because stimulants can worsen agitation or anxiety [9, 21]. Question 3. An 8-year-old boy recently diagnosed with ADHD is prescribed a methylphenidate stimulant, Ritalin SR, as an initial treatment. At the follow-up visit two weeks later, the mother reports some improvement in ADHD symptoms, but she has noticed the development of a tic consisting of eye blinking and neck jerking. The PMHNP recommends: A. Increasing the dose of methylphenidate B. Switching to methylphenidate extended release like Concerta C. Switching to atomoxetine D. Adding bupropion to his regimen Pause. Answer: C. Why correct: When new motor tics emerge following stimulant initiation, the safest clinical approach is to discontinue the stimulant and switch to a non-stimulant such as atomoxetine [8, 10]. Why the other choices are wrong: * A: Incorrect because increasing the methylphenidate dose will further aggravate tic severity source 10. * B: Incorrect because changing to a long-acting methylphenidate formulation continues dopamine and norepinephrine reuptake inhibition, sustaining tics source 10. * C: Correct option source 10. * D: Incorrect because adding bupropion lowers the seizure threshold and fails to eliminate the stimulant-induced tic trigger [10, 24]. Question 4. When initiating methylphenidate therapy for a 9-year-old boy with ADHD, the PMHNP educates the family on the possibility of all of the following potential adverse effects except: A. Headache B. Hypersomnia C. Loss of appetite or weight loss D. Exacerbation of tic disorder Pause. Answer: B. Why correct: Stimulants cause central nervous system arousal leading to insomnia, not hypersomnia source 25. Why the other choices are wrong: * A: Incorrect because transient headaches are a known initial adverse effect of methylphenidate source 26. * B: Correct as the exception, because stimulants cause insomnia rather than hypersomnia source 25. * C: Incorrect because appetite suppression and weight loss are major adverse effects requiring quarterly tracking [2, 26]. * D: Incorrect because unmasking or worsening of motor tics is a recognized stimulant risk source 26. Next. Topic. Behavioral Activation and AIM Side Effects. Bottom Line. - Only two SSRIs carry FDA approval for pediatric major depressive disorder: **fluoxetine** for children aged 8 and older, and **escitalopram** for adolescents aged 12 and older source 1. - All antidepressants carry an FDA **black box warning** for an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under age 25 [1, 2]. - **Behavioral activation** from SSRIs in pediatric patients presents as motor restlessness, agitation, impulsivity, insomnia, or disinhibition, which correlates directly with drug initiation or dose escalation rather than episodic bipolar cycling source 2. - Baseline and quarterly physical monitoring for pediatric patients on stimulant pharmacotherapy requires measuring height, weight, blood pressure, and pulse to track growth suppression and cardiovascular changes [3, 4]. - Behavioral therapy is the recommended **first-line** intervention for ADHD in children under 5 years of age before considering stimulant pharmacotherapy source 4. - Approximately 20% of children with ADHD develop a chronic tic disorder independently, and stimulants can unmask or worsen motor tics such as eye blinking or neck jerking [5, 6]. - When motor tics emerge or worsen on a stimulant, the recommended management is to switch to a non-stimulant such as **atomoxetine** [7, 8]. - Stimulant pharmacotherapy requires caution or avoidance in pediatric patients with hypertension, structural cardiac abnormalities, active motor tics, prior substance use disorder, or severe anxiety and agitation [9, 10]. Pediatric Psychopharmacology and Clinical Teaching. FDA Approvals and Black Box Warning. - **First-line** antidepressant pharmacotherapy for pediatric major depressive disorder is limited to two FDA-approved SSRIs: **fluoxetine** for patients aged 8 and older, and **escitalopram** for patients aged 12 and older source 1. - Tricyclic antidepressants are not recommended as second-line therapy in children due to lack of pediatric efficacy and significant cardiotoxicity risks [11, 12]. - **Safety alert:** All antidepressants carry an FDA **black box warning** for increased suicidal ideation and suicidal behaviors in children, adolescents, and young adults up to age 25 [1, 2]. Close clinical monitoring is essential during the initial weeks of treatment and after dose increases source 2. Behavioral Activation versus Bipolar Mania. - **Safety alert:** Behavioral activation is a known adverse effect of SSRI therapy in pediatric populations, characterized by motor agitation, restlessness, impulsivity, insomnia, and behavioral disinhibition source 2. - **Board trap:** Do not confuse SSRI-induced behavioral activation with the onset of pediatric bipolar mania. Bipolar disorder is an episodic illness marked by distinct cycles of altered mood and grandiosity, whereas behavioral activation directly correlates with antidepressant initiation or dose escalation [2, 13]. - Prepubertal onset of depression and a multigenerational family history of mood disorders elevate the risk of a child later transitioning from depression to bipolar disorder source 2. Stimulant Side Effects and Physical Monitoring. - **First-line** pharmacological treatment for ADHD in children aged 6 and older includes stimulants such as **methylphenidate** or **dextroamphetamine** [3, 14]. For children under age 5, behavioral therapy is the recommended initial intervention source 4. - **Safety alert:** Required physical monitoring for pediatric patients taking stimulants includes baseline and quarterly measurements of height, weight, blood pressure, and pulse [3, 4]. - Common stimulant adverse effects include loss of appetite, weight loss, transient headaches, insomnia, and potential growth velocity suppression [3, 15, 16]. Hypersomnia is not an adverse effect of stimulant therapy source 15. Movement Side Effects and Tic Management. - Approximately 20% of children with ADHD develop chronic tics, and 50% of children with Tourette syndrome have comorbid ADHD source 5. - **Board trap:** When a child on a methylphenidate or dextroamphetamine stimulant develops new motor tics such as eye blinking or neck jerking, do not increase the stimulant dose or switch to another stimulant formulation source 8. - **First-line** adjustment for stimulant-induced or exacerbated motor tics is switching to a non-stimulant medication such as **atomoxetine** or an alpha-2 adrenergic agonist [3, 7, 8]. Sample Board Questions. Question 1. Katana, a 14-year-old girl, meets the diagnostic criteria for major depressive disorder. Which of the following statements is true regarding depression treatment in children and adolescents? [1, 17, 18] A) Fluoxetine is one of only two medications FDA approved for use with adolescents. B) Children require lower doses of antidepressants. C) Psychopharmacology is more effective than psychotherapy. D) Tricyclic antidepressants offer a reasonable second line option. Pause. Answer: A source 1. Why it is correct: **Fluoxetine** (approved for ages 8 and older) and **escitalopram** (approved for ages 12 and older) are the only two FDA-approved antidepressants for pediatric major depressive disorder source 1. Why the other choices are wrong: - A: This choice is correct because fluoxetine and escitalopram are the only two FDA-approved pediatric antidepressants source 1. - B: Children do not necessarily require lower antidepressant doses than adults due to their higher hepatic metabolic clearance source 1. - C: Psychotherapy is highly effective and often preferred initially or combined with pharmacotherapy source 11. - D: Tricyclic antidepressants are not recommended as second-line options in children due to cardiotoxicity risks and lack of demonstrated pediatric efficacy [11, 12]. Question 2. An 8-year-old boy recently diagnosed with ADHD is prescribed a methylphenidate stimulant, Ritalin SR, as initial treatment. At the follow-up visit 2 weeks later, his mother reports symptom improvement, but she notes the development of a motor tic consisting of eye blinking and neck jerking. The PMHNP recommends which of the following actions? [6, 8] A) Increasing the dose of methylphenidate by switching to Concerta. B) Switching to methylphenidate extended release. C) Switching to atomoxetine. D) Adding bupropion to his regimen. Pause. Answer: C [8, 19]. Why it is correct: When motor tics develop or worsen during stimulant therapy, the appropriate clinical action is to switch to a non-stimulant such as **atomoxetine** [8, 19]. Why the other choices are wrong: - A: Increasing the stimulant dose or switching to Concerta will further worsen motor tics source 8. - B: Switching to another formulation of methylphenidate maintains stimulant exposure and fails to resolve tic exacerbation source 8. - C: This choice is correct because atomoxetine is an effective non-stimulant that does not exacerbate tics [8, 19]. - D: Adding bupropion is not a first-line strategy for stimulant-induced tics and carries its own risk profile source 8. Question 3. When initiating methylphenidate therapy for a 9-year-old boy with ADHD, the PMHNP educates the family on the possibility of all of the following potential adverse effects except: [15, 20] A) Headache B) Hypersomnia C) Loss of appetite or weight loss D) Exacerbation of tic disorder Pause. Answer: B source 15. Why it is correct: Stimulants cause central nervous system arousal leading to insomnia rather than hypersomnia source 15. Why the other choices are wrong: - A: Transient headache is a known adverse effect when initiating methylphenidate source 16. - B: This choice is correct because hypersomnia is not a side effect of stimulant therapy source 15. - C: Anorexia, appetite suppression, and weight loss are common adverse effects of methylphenidate source 16. - D: Methylphenidate can unmask or exacerbate underlying motor and vocal tic disorders source 16. Question 4. When considering the management of ADHD in a 15-year-old adolescent, the use of a stimulant medication should be avoided or used with caution in the presence of which of the following conditions? Select all that apply. [9, 10, 21] A) Hypertension B) Cardiac abnormality C) Type 2 diabetes D) Prior history of substance use disorder E) Presence of motor tics F) History of anxiety or agitated states Pause. Answer: A, B, D, E, F source 10. Why it is correct: Stimulant medications require caution or avoidance in patients with hypertension, structural cardiac abnormalities, prior substance use history, active motor tics, and severe anxiety or agitation due to sympathomimetic effects source 10. Why the other choices are wrong: - A: Hypertension requires caution because stimulants elevate blood pressure source 10. - B: Cardiac abnormalities require caution due to risks of adverse cardiovascular events source 10. - C: Type 2 diabetes is not a contraindication or caution for stimulant therapy [10, 22]. - D: Prior substance use history requires caution due to the abuse potential of Schedule II stimulants source 10. - E: Active motor tics require caution because stimulants can exacerbate tic frequency and severity source 10. - F: Anxiety or agitated states require caution because stimulants can heighten central nervous system arousal source 10. 🧠 Would you like to review the next leaf in Chapter 15, such as Mood, Anxiety, OCD, and Trauma Presentations in Youth? Next. New section. Table 15-1: Developmental Milestone Inventory. Topic. Sample Question: 32-month-old Development. Bottom Line. - Babbling begins between **5 and 7 months** of age. - Sitting alone for 30 seconds occurs between **6 and 8 months** of age. - Stranger anxiety typically emerges between **8 and 10 months** of age. - Saying specific words like mama or dada occurs between **10 and 12 months** of age. - Walking solo occurs between **12 and 18 months** of age. - Kicking a ball using large muscle groups occurs between **18 and 30 months** of age. - Two-word sentences develop between **2 and 3 years** of age. - Speech intelligible to strangers 75% of the time develops between **3 and 4 years** of age. - Parallel play and imaginary friends are normal at 32 months, while interactive peer play begins between **3 and 4 years** of age. Table 15-1: Developmental Milestone Inventory. Language milestones progress sequentially across infancy and early childhood. Babbling opens language development between 5 and 7 months. Specific words like mama or dada emerge between 10 and 12 months. Two-word sentences develop between 2 and 3 years. Speech becomes 75 percent intelligible to strangers between 3 and 4 years. Motor milestones advance from postural stability to complex muscle coordination. Sitting alone for 30 seconds is achieved between 6 and 8 months. Solo walking follows between 12 and 18 months. Kicking a ball with larger muscle groups matures between 18 and 30 months. Social and emotional milestones begin with stranger anxiety between 8 and 10 months. Parallel play and imaginary friends are normal behaviors at 32 months. Active, cooperative peer play develops between 3 and 4 years. First-line: Parental education and reassurance is the first-line intervention when a caregiver expresses concern over normal developmental behaviors like parallel play or imaginary friends. Board trap: Do not confuse normal parallel play in toddlers under 3 years of age with social detachment or **autism spectrum disorder**. Exam stems use parental anxiety to tempt test-takers into ordering unnecessary referrals or diagnostic workups. Safety alert: Any clear loss or regression of previously mastered developmental milestones is an emergency signal that requires immediate comprehensive developmental and neurological evaluation. Sample Question: 32-month-old Development. Question 1. Question: A mother is concerned that her 32-month-old daughter is not interested in playing with other children, but describes her imaginary friend. The appropriate approach would be to: - A. Reassure the mother that this is consistent with normal development. - B. Refer the child to early intervention for further evaluation. - C. Determine whether or not there is a history of autism spectrum disorder or ASD among siblings and or parents. - D. Advise that the child be evaluated by a pediatrician. Pause. Answer: A Why correct: Parallel play and imaginary friends in a 32-month-old child are expected developmental findings. Children at this stage play alongside peers rather than in interactive groups. Cooperative peer play develops later, between 3 and 4 years of age. Educating and reassuring the parent is the correct independent advanced practice action [1-7]. Why the other choices are wrong: - A. Correct option. - B. Referral to early intervention is incorrect because the child demonstrates normal age-appropriate social and imaginative development [6, 7]. - C. Family history screening for **autism spectrum disorder** is unnecessary because lack of group play at 32 months is a normal milestone, not a pathologic sign [6, 7]. - D. Referring to a pediatrician is incorrect because the advanced practice nurse possesses the clinical expertise to evaluate milestones independently and reassure the mother [6, 7]. Next. New section. Adolescent Confidentiality and HEADDS Tool. Topic. Sample Question: Kitana and Parental Consent. Bottom Line Summary. * **Fluoxetine** is FDA approved for major depressive disorder in pediatric patients down to age 8, while **escitalopram** is approved down to age 12. * General psychiatric treatment of a minor requires parental or guardian consent, whereas state exceptions allow minors to consent independently for family planning, reproductive care, STI testing, and substance use treatment. * Non-suicidal self-injury, such as superficial cutting without suicidal intent, does not legally mandate parental disclosure if reporting would destroy therapeutic trust and there is no active safety threat. * Confidentiality must be broken immediately when an adolescent expresses active suicidal ideation with intent, homicidal ideation, or ongoing physical or sexual abuse. * The **HEADSS** mnemonic structures adolescent psychosocial screening across Home, Education, Activities, Drugs, Sex, and Suicidality. * **Tricyclic antidepressants** are contraindicated as second-line treatment for pediatric depression due to cardiotoxicity and lethal overdose risk. * All antidepressants carry an FDA **Black Box Warning** for increased suicidal thoughts and behaviors in patients under age 25. High-Yield Clinical Concepts and Spoken Teaching. Adolescent Confidentiality and Parental Consent Framework. Evaluating adolescent patients requires balancing legal mandates with the therapeutic relationship. Initial visits must establish clear confidentiality boundaries with both the youth and their caregivers. Parents do not possess an automatic legal right to review private psychotherapy notes or disclosures made during individual sessions. **First-Line**: For mild to moderate pediatric depression, psychotherapy such as cognitive behavioral therapy is first-line treatment. When medication is required, **fluoxetine** or **escitalopram** are first-line agents. **Safety Alert**: Breach confidentiality and notify parents or emergency authorities immediately if an adolescent reveals active suicidal intent, a concrete suicide plan, homicidal ideation, or active child abuse. **Board Trap**: Do not confuse general psychiatric care with protected minor healthcare services. Parental consent is legally required before initiating routine psychiatric treatment or psychotropic medications in minors. However, most states permit adolescents to consent independently for substance use disorder treatment, contraception, and sexually transmitted infection management. **Board Trap**: Do not assume non-suicidal self-injury mandates breaking confidentiality. Superficial cutting undertaken as an unhealthy coping mechanism without suicidal intent does not automatically require parental notification. Conversely, cutting accompanied by suicidal intent constitutes an active emergency that requires immediate parental involvement and safety intervention. Psychosocial Screening via the HEADSS Tool. The **HEADSS** mnemonic provides a systematic framework for gathering sensitive adolescent history: * **H**: Home environment, family stability, and living arrangements. * **E**: Education, school performance, attendance, and employment plans. * **A**: Activities, peer relationships, hobbies, and screen time. * **D**: Drugs, alcohol, tobacco, and vaping habits. * **S**: Sex, sexuality, contraception, and gender identity. * **S**: Suicidality, self-harm, mood, and overall mental health. Board Practice Questions. Question 1. Kitana is a 14-year-old girl seen in your clinic for evaluation because her mother found that she had been using a razor blade to cut her wrist. Which of the following is false regarding parental consent? A. She can receive family planning assistance without parental consent. B. You do not require parental consent before treating a psychiatric condition. C. Most states will allow you to provide information and treatment for substance use disorder without parental consent. D. Providers are not required to report self-harm behaviors, such as cutting to the child's parents or guardians. Pause. Answer. **Best Answer**: B **Why It Is Correct**: Statement B is false, which makes it the correct choice. Treating a general psychiatric condition in a 14-year-old minor legally requires parental or guardian consent under standard healthcare law. **Why the Other Choices Are Wrong**: * **A**: Incorrect because the statement is true; adolescents can legally access reproductive health and family planning services without parental consent in most jurisdictions. * **C**: Incorrect because the statement is true; most state statutes allow minors to seek confidential information and treatment for substance use disorders without parental notification. * **D**: Incorrect because the statement is true; providers are not legally required to report non-suicidal self-injury like superficial cutting to parents if the patient lacks suicidal intent and reporting would destroy the therapeutic alliance. **Test-Taking Pearl**: Distinguish general psychiatric care, which requires parental consent, from state-protected minor consent exceptions including family planning, STI testing, and substance use treatment. Question 2. Kitana, the 14-year-old patient from the prior scenario, meets full diagnostic criteria for major depressive disorder. Which of the following is true regarding depression treatment in children and adolescents? A. Fluoxetine is one of only two medications FDA approved for use with adolescents. B. Children require lower doses of antidepressants. C. Psychopharmacology is more effective than psychotherapy. D. Tricyclic antidepressants offer a reasonable second line option. Pause. Answer. **Best Answer**: A **Why It Is Correct**: Statement A is true. **Fluoxetine** and **escitalopram** are the only two SSRIs with FDA approval for treating major depressive disorder in pediatric and adolescent populations. **Why the Other Choices Are Wrong**: * **B**: Incorrect because youth often possess faster hepatic clearance than adults, frequently requiring comparable adult antidepressant doses rather than lower doses. * **C**: Incorrect because psychotherapy alone or combined with medication is highly effective, and pharmacotherapy is not inherently superior to psychotherapy in youth. * **D**: Incorrect because **tricyclic antidepressants** carry severe cardiotoxicity risks, lethal overdose potential, and lack demonstrated efficacy in pediatric depression. **Test-Taking Pearl**: Memorize the exact FDA pediatric age cutoffs for depression: **fluoxetine** is approved down to age 8, and **escitalopram** is approved down to age 12. 💡 **Next Study Step**: Review Fitzgerald Chapter 15 content on Attention-Deficit/Hyperactivity Disorder (ADHD) diagnostic criteria, age thresholds, and stimulant versus non-stimulant management. Next. End of this drive.